Abstract
In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart. The increase in forced expiratory volume in 1 s (FEV1) above baseline was significantly greater after ICI 204,219 than after placebo. This effect persisted after nebulised salbutamol. These findings suggest that cysteinyl-leukotrienes are one of the causes of persistent bronchoconstriction in chronic asthma.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Inhalation
-
Adult
-
Airway Resistance / drug effects
-
Albuterol / administration & dosage
-
Albuterol / therapeutic use
-
Asthma / drug therapy*
-
Asthma / physiopathology
-
Bronchoconstriction / drug effects
-
Double-Blind Method
-
Drug Evaluation
-
Female
-
Forced Expiratory Volume / drug effects
-
Humans
-
Indoles
-
Leukotriene Antagonists*
-
Male
-
Middle Aged
-
Phenylcarbamates
-
Sulfonamides
-
Tosyl Compounds / therapeutic use*
Substances
-
Indoles
-
Leukotriene Antagonists
-
Phenylcarbamates
-
Sulfonamides
-
Tosyl Compounds
-
Albuterol
-
zafirlukast